483
Biovectra Inc.Biovectra Inc. – FDA 483, Sep 12, 2024
Record Details
An FDA inspection of BIOVECTRA Inc. in Windsor, Nova Scotia, revealed numerous deficiencies in their drug substance manufacturing processes. Key issues included inadequate microbial control, insufficient deviation investigations, and poor adherence to and validation of standard operating procedures. The findings indicate a lack of robust quality systems and controls over critical aspects of drug substance production.
View Company Profile
ID · 690ec542-5cf2-49c8-b4ab-8624d6eb0ab8
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.